DK2702155T3 - Mikro-rna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet - Google Patents
Mikro-rna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet Download PDFInfo
- Publication number
- DK2702155T3 DK2702155T3 DK12718549.4T DK12718549T DK2702155T3 DK 2702155 T3 DK2702155 T3 DK 2702155T3 DK 12718549 T DK12718549 T DK 12718549T DK 2702155 T3 DK2702155 T3 DK 2702155T3
- Authority
- DK
- Denmark
- Prior art keywords
- nucleoside
- fibrosis
- mir
- certain embodiments
- certain aspects
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
Claims (15)
1. Forbindelse, der omfatter et modificeret oligonukleotid, der består af nukleobasesekvensen og modifikationerne: AeCgATCcAGTCsTGAUgAAGCsTAe ; hvor nukleosider, der ikke følges af et sænket bogstav, er β-D-deoxyribonukleosider, nukleosider, der følges af et sænket "E", er 2'-MOE-nukleosider, nukleosider, der følges af et sænket "S", er S-cEt-nukleosider; og hvor hver internukleosidbinding er en phosphorthioat- internukleosidbinding.
2. Forbindelse ifølge krav 1, der består af det modificerede oligonukleotid.
3. Farmaceutisk sammensætning, der omfatter en forbindelse ifølge krav 1 eller krav 2 og et farmaceutisk acceptabelt bæremateriale.
4. Forbindelse ifølge krav 1 eller krav 2 eller en farmaceutisk sammensætning ifølge krav 3 til anvendelse til terapi.
5. Forbindelse eller sammensætning ifølge krav 4 til anvendelse til behandling af fibrose.
6. Forbindelse ifølge krav 1 eller krav 2 eller farmaceutisk sammensætning ifølge krav 3 til anvendelse i en fremgangsmåde til behandling, forebyggelse eller forsinkelse af debuten af en sygdom, der er forbundet med miR-21, som omfatter administrering af forbindelsen eller sammensætningen til et individ, der har en sygdom, der er forbundet med miR-21, hvor sygdommen er fibrose, såsom en fibrose udvalgt blandt nyrefibrose, lungefibrose, leverfibrose, hjertefibrose, hudfibrose, aldersrelateret fibrose, miltfibrose, sklerodermi og posttransplantationsfibrose.
7. Forbindelse eller sammensætning ifølge krav 6, hvor fibrosen er nyrefibrose.
8. Forbindelse eller sammensætning ifølge krav 7, hvor: a) nyrefibrosen er til stede hos et individ, der har en sygdom udvalgt blandt glomerulosklerose, tubulointerstitiel fibrose, IgA-nefropati, interstitiel fibrose/tubulær atrofi; kronisk nyreskade, glomerulær sygdom, glomerulonefritis, diabetes mellitus, idiopatisk fokal segmental glomerulosklerose, membranøs nefropati, kollaberende glomerulopati, kronisk recidiverende nyreinfektion og slutstadiet af nyresygdom; eller b) nyrefibrosen skyldes akut eller repetitiv traume af nyren.
9. Forbindelse eller sammensætning ifølge et hvilket som helst af kravene 6-8, hvor fremgangsmåden omfatter selektion af et individ, der har forhøjet miR-21-ekspression i et eller flere væv.
10. Forbindelse eller sammensætning ifølge et hvilket som helst af kravene 6-9, hvor fremgangsmåden omfatter administrering af mindst ét terapeutisk middel udvalgt blandt et antiinflammatorisk middel, et immunsuppressivt middel, et antidiabetisk middel, digoxin, en vasodilatator, en angiotensin Il-konverterende enzym (ACE)-inhibitor, en angiotensin II-receptorblokker (ARB), en calciumkanalblokker, et isosorbiddinitrat, en hydralazin, et nitrat, en hydralazin, en betablokker, et natriuretisk peptid, et heparinoid og en bindevævs-vækstfaktorinhibitor.
11. Forbindelse eller sammensætning ifølge krav 10, hvor fremgangsmåden omfatter administrering af mindst én ACE-inhibitor.
12. Forbindelse eller sammensætning ifølge krav 11, hvor ACE- inhibitoren er udvalgt blandt captopril, enalapril, lisinopril, benazepril, quinapril, fosinopril og ramipril.
13. Forbindelse eller sammensætning ifølge krav 10, hvor fremgangsmåden omfatter administrering af mindst én ARB- inhibitor.
14. Forbindelse eller sammensætning ifølge krav 13, hvor ARB-inhibitoren er udvalgt blandt candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan og eprosartan.
15. Forbindelse eller sammensætning ifølge et hvilket som helst af kravene 6-14, hvor individet er et menneske.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478767P | 2011-04-25 | 2011-04-25 | |
US201161565779P | 2011-12-01 | 2011-12-01 | |
PCT/US2012/034880 WO2012148952A1 (en) | 2011-04-25 | 2012-04-25 | Microrna compounds and methods for modulating mir-21 activity |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2702155T3 true DK2702155T3 (da) | 2017-05-01 |
Family
ID=46025979
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12718549.4T DK2702155T3 (da) | 2011-04-25 | 2012-04-25 | Mikro-rna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet |
DK17153724.4T DK3211082T3 (da) | 2011-04-25 | 2012-04-25 | Mikrorna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17153724.4T DK3211082T3 (da) | 2011-04-25 | 2012-04-25 | Mikrorna-forbindelser og fremgangsmåder til modulering af mir-21-aktivitet |
Country Status (30)
Country | Link |
---|---|
US (7) | US20120270928A1 (da) |
EP (3) | EP2702155B9 (da) |
JP (2) | JP6320292B2 (da) |
KR (2) | KR20190063482A (da) |
CN (3) | CN103620035B (da) |
AU (4) | AU2012249851B2 (da) |
BR (1) | BR112013027187A2 (da) |
CA (2) | CA2833615C (da) |
CL (1) | CL2013003105A1 (da) |
CO (1) | CO6821889A2 (da) |
CY (1) | CY1120304T1 (da) |
DK (2) | DK2702155T3 (da) |
EA (1) | EA025894B1 (da) |
ES (2) | ES2621863T3 (da) |
HK (1) | HK1243130A1 (da) |
HR (2) | HRP20170557T2 (da) |
HU (2) | HUE054129T2 (da) |
IL (3) | IL229032B (da) |
LT (2) | LT2702155T (da) |
MX (5) | MX2013012452A (da) |
MY (2) | MY175336A (da) |
NZ (1) | NZ717921A (da) |
PL (2) | PL2702155T3 (da) |
PT (2) | PT3211082T (da) |
RS (1) | RS61775B1 (da) |
SG (1) | SG194636A1 (da) |
SI (2) | SI3211082T1 (da) |
TW (2) | TWI698445B (da) |
UA (1) | UA115652C2 (da) |
WO (1) | WO2012148952A1 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173611B2 (en) | 2004-11-12 | 2012-05-08 | Asuragen Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
TWI698445B (zh) * | 2011-04-25 | 2020-07-11 | 法商賽諾菲公司 | 微型rna化合物及調控mir-21活性之方法 |
WO2013153082A1 (en) * | 2012-04-10 | 2013-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of nonalcoholic steatohepatitis |
JP6322189B2 (ja) | 2012-04-25 | 2018-05-09 | レグルス セラピューティクス インコーポレイテッド | Mir−21活性を調節するためのマイクロrna化合物及び方法 |
UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
JP2016503300A (ja) | 2012-11-15 | 2016-02-04 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S | 抗ApoBアンチセンス複合体化合物 |
AU2014259954B2 (en) * | 2013-05-01 | 2019-11-07 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-122 |
EP3060664B1 (en) | 2013-10-25 | 2021-07-07 | Sanofi | Microrna compounds and methods for modulating mir-21 activity |
KR101625755B1 (ko) | 2013-11-18 | 2016-05-30 | 울산대학교 산학협력단 | miRNA 스폰지 및 이의 용도 |
JP2017505623A (ja) * | 2014-01-30 | 2017-02-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 生物切断性コンジュゲートを有するポリオリゴマー化合物 |
CN105734127A (zh) * | 2016-02-29 | 2016-07-06 | 上海中医药大学 | miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途 |
WO2017187426A1 (en) * | 2016-04-29 | 2017-11-02 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
CN111386351A (zh) | 2017-09-22 | 2020-07-07 | 华盛顿大学 | 细胞分子的原位组合标记 |
CN108148911B (zh) * | 2018-03-02 | 2019-11-05 | 广州医科大学附属第二医院 | miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用 |
JP7279081B2 (ja) | 2018-05-08 | 2023-05-22 | レグルス セラピューティクス インコーポレイテッド | Mir-122を調節するためのマイクロrna化合物及び方法 |
CN110747266A (zh) * | 2018-07-23 | 2020-02-04 | 深圳先进技术研究院 | miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用 |
CN109880907A (zh) * | 2019-03-26 | 2019-06-14 | 中国人民解放军第八一医院 | 一种肝癌细胞侵袭转移的分子机制研究方法 |
US11965162B2 (en) | 2020-04-16 | 2024-04-23 | The Johns Hopkins University | MicroRNA and inhibitors thereof and methods of treatment |
WO2022165092A1 (en) * | 2021-01-29 | 2022-08-04 | Angion Biomedica Corp. | Methods for treatment of fibrotic diseases |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060008817A1 (en) * | 2000-12-08 | 2006-01-12 | Invitrogen Corporation | Methods and compositions for generating recombinant nucleic acid molecules |
EP2385123B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
ATE555118T1 (de) | 2003-08-28 | 2012-05-15 | Takeshi Imanishi | Neue synthetische nukleidsäuren vom typ mit quervernetzter n-o-bindung |
EP1791567B1 (en) | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
US8173611B2 (en) | 2004-11-12 | 2012-05-08 | Asuragen Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
EP1959012A3 (en) | 2004-12-29 | 2009-12-30 | Exiqon A/S | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAs and their target mRNAs |
US6995235B1 (en) | 2005-05-02 | 2006-02-07 | Univation Technologies, Llc | Methods of producing polyolefins and films therefrom |
DK1931780T3 (da) | 2005-08-29 | 2016-01-25 | Regulus Therapeutics Inc | Antisense-forbindelser med forøget anti-microrna-aktivitet |
JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ, インコーポレーテッド | 6−修飾された二環式核酸類似体 |
JP5213723B2 (ja) | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ, インコーポレーテッド | マイクロrnaの調節に使用するためのオリゴマー化合物及び組成物 |
WO2007112754A2 (en) | 2006-04-03 | 2007-10-11 | Santaris Pharma A/S | Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides |
EP3502255A1 (en) * | 2006-04-03 | 2019-06-26 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition |
AU2007303205A1 (en) | 2006-10-03 | 2008-04-10 | Tekmira Pharmaceuticals Corporation | Lipid containing formulations |
EP2094869B1 (de) | 2006-10-09 | 2012-07-25 | Julius-Maximilians-Universität Würzburg | Microrna (mirna) zur diagnose und therapie von herzerkrankungen |
AU2007333107A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
US8048998B2 (en) | 2007-01-19 | 2011-11-01 | Exiqon A/S | Mediated cellular delivery of LNA oligonucleotides |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
WO2008151631A2 (en) | 2007-06-15 | 2008-12-18 | Exiqon A/S | Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis |
CN101796062B (zh) | 2007-07-05 | 2014-07-30 | Isis制药公司 | 6-双取代双环核酸类似物 |
US8440637B2 (en) * | 2007-10-04 | 2013-05-14 | Santaris Pharma A/S | Combination treatment for the treatment of hepatitis C virus infection |
CN101980712B (zh) | 2007-10-29 | 2015-02-18 | 雷古拉斯治疗公司 | 用于肝癌治疗的靶向微小rna |
US20110257244A1 (en) | 2008-01-18 | 2011-10-20 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof |
EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
WO2010099161A1 (en) * | 2009-02-26 | 2010-09-02 | The Ohio State University Research Foundation | Micrornas in never-smokers and related materials and methods |
AU2010258875A1 (en) * | 2009-06-08 | 2012-01-19 | Miragen Therapeutics | Chemical modification motifs for miRNA inhibitors and mimetics |
WO2011126842A2 (en) | 2010-03-30 | 2011-10-13 | Regulus Therapeutics Inc. | Targeting micrornas for the treatment of cardiac disorders |
TWI698445B (zh) | 2011-04-25 | 2020-07-11 | 法商賽諾菲公司 | 微型rna化合物及調控mir-21活性之方法 |
WO2013013165A2 (en) | 2011-07-21 | 2013-01-24 | The Trustees Of The University Of Pennsylvania | Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
JP6322189B2 (ja) | 2012-04-25 | 2018-05-09 | レグルス セラピューティクス インコーポレイテッド | Mir−21活性を調節するためのマイクロrna化合物及び方法 |
CA2876180C (en) | 2012-06-21 | 2019-11-19 | MiRagen Therapeutics, Inc. | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
JP6352269B2 (ja) | 2012-09-26 | 2018-07-04 | ミルクス セラピューティクス アクティーゼルスカブMirrx Therapeutics A/S | オフターゲットプロファイルの改善されたオリゴマー |
UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
-
2012
- 2012-04-25 TW TW106131684A patent/TWI698445B/zh active
- 2012-04-25 EP EP12718549.4A patent/EP2702155B9/en active Active
- 2012-04-25 HU HUE17153724A patent/HUE054129T2/hu unknown
- 2012-04-25 KR KR1020197015054A patent/KR20190063482A/ko not_active Application Discontinuation
- 2012-04-25 BR BR112013027187A patent/BR112013027187A2/pt not_active Application Discontinuation
- 2012-04-25 MX MX2013012452A patent/MX2013012452A/es unknown
- 2012-04-25 WO PCT/US2012/034880 patent/WO2012148952A1/en active Application Filing
- 2012-04-25 MY MYPI2013003885A patent/MY175336A/en unknown
- 2012-04-25 SI SI201231913T patent/SI3211082T1/sl unknown
- 2012-04-25 HU HUE12718549A patent/HUE031595T2/en unknown
- 2012-04-25 CA CA2833615A patent/CA2833615C/en active Active
- 2012-04-25 DK DK12718549.4T patent/DK2702155T3/da active
- 2012-04-25 LT LTEP12718549.4T patent/LT2702155T/lt unknown
- 2012-04-25 EP EP21157334.0A patent/EP3933040A1/en not_active Withdrawn
- 2012-04-25 SG SG2013079454A patent/SG194636A1/en unknown
- 2012-04-25 DK DK17153724.4T patent/DK3211082T3/da active
- 2012-04-25 SI SI201230924A patent/SI2702155T1/sl unknown
- 2012-04-25 ES ES12718549.4T patent/ES2621863T3/es active Active
- 2012-04-25 UA UAA201312414A patent/UA115652C2/uk unknown
- 2012-04-25 US US13/455,337 patent/US20120270928A1/en active Pending
- 2012-04-25 AU AU2012249851A patent/AU2012249851B2/en active Active
- 2012-04-25 JP JP2014508494A patent/JP6320292B2/ja active Active
- 2012-04-25 PL PL12718549T patent/PL2702155T3/pl unknown
- 2012-04-25 EA EA201391492A patent/EA025894B1/ru not_active IP Right Cessation
- 2012-04-25 US US14/111,976 patent/US9181547B2/en active Active
- 2012-04-25 RS RS20210552A patent/RS61775B1/sr unknown
- 2012-04-25 CN CN201280031285.4A patent/CN103620035B/zh active Active
- 2012-04-25 PT PT171537244T patent/PT3211082T/pt unknown
- 2012-04-25 MY MYPI2017000706A patent/MY187685A/en unknown
- 2012-04-25 ES ES17153724T patent/ES2868950T3/es active Active
- 2012-04-25 NZ NZ717921A patent/NZ717921A/en unknown
- 2012-04-25 PL PL17153724T patent/PL3211082T3/pl unknown
- 2012-04-25 KR KR1020137031227A patent/KR102055172B1/ko active IP Right Grant
- 2012-04-25 PT PT127185494T patent/PT2702155T/pt unknown
- 2012-04-25 TW TW101114636A patent/TWI607016B/zh active
- 2012-04-25 EP EP17153724.4A patent/EP3211082B1/en active Active
- 2012-04-25 LT LTEP17153724.4T patent/LT3211082T/lt unknown
- 2012-04-25 CA CA3165397A patent/CA3165397A1/en active Pending
- 2012-04-25 CN CN202110384864.8A patent/CN113151272A/zh active Pending
- 2012-04-25 CN CN202110383567.1A patent/CN113249381A/zh active Pending
-
2013
- 2013-10-23 IL IL229032A patent/IL229032B/en active IP Right Grant
- 2013-10-23 MX MX2022000212A patent/MX2022000212A/es unknown
- 2013-10-23 MX MX2022006595A patent/MX2022006595A/es unknown
- 2013-10-23 MX MX2019003089A patent/MX2019003089A/es unknown
- 2013-10-23 MX MX2019003090A patent/MX2019003090A/es unknown
- 2013-10-25 CL CL2013003105A patent/CL2013003105A1/es unknown
- 2013-10-30 CO CO13257480A patent/CO6821889A2/es unknown
-
2014
- 2014-07-28 US US14/444,406 patent/US8912161B2/en active Active
-
2015
- 2015-10-14 US US14/883,055 patent/US9790496B2/en active Active
-
2017
- 2017-04-06 HR HRP20170557TT patent/HRP20170557T2/hr unknown
- 2017-04-25 CY CY20171100460T patent/CY1120304T1/el unknown
- 2017-08-29 AU AU2017219156A patent/AU2017219156B2/en active Active
- 2017-09-14 US US15/704,749 patent/US20180155719A1/en not_active Abandoned
-
2018
- 2018-02-23 HK HK18102629.5A patent/HK1243130A1/zh unknown
- 2018-04-02 JP JP2018070694A patent/JP2018121646A/ja active Pending
-
2019
- 2019-05-08 IL IL266529A patent/IL266529A/en unknown
-
2020
- 2020-01-24 US US16/751,402 patent/US20200291400A1/en not_active Abandoned
- 2020-02-26 AU AU2020201403A patent/AU2020201403A1/en not_active Abandoned
- 2020-03-18 IL IL273381A patent/IL273381A/en unknown
-
2021
- 2021-04-19 HR HRP20210616TT patent/HRP20210616T1/hr unknown
- 2021-08-18 US US17/405,482 patent/US20220098583A1/en active Pending
-
2022
- 2022-05-06 AU AU2022203067A patent/AU2022203067A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220098583A1 (en) | MicroRNA Compounds and Methods for Modulating MIR-21 Activity | |
US9970009B2 (en) | MicroRNA compounds and methods for modulating miR-21 activity | |
EP3060664A1 (en) | Microrna compounds and methods for modulating mir-21 activity | |
NZ616748B2 (en) | Microrna compounds and methods for modulating mir-21 activity |